However, other studies have found that CSF sTREM2 has a dynamic response in the tracking of AD progression (Suárez-Calvet et al., 2016c, 2019; Ma et al., 2020), and a study in patients with MCI or AD dementia who had A+ and T+ biomarkers found that higher concentrations of sTREM2 in CSF were associated with reduced memory decline, lower CSF p-tau levels, and hippocampal shrinkage (Ewers et al., 2019). The gene discussed is MAPT; the disease is dementia.